Paragon Biosciences is a pioneering global leader in life sciences, dedicated to creating, building, and funding innovative biology-based companies focused on treating and curing diseases. Their mission is to accelerate life science innovation through a robust portfolio of companies that address significant unmet medical needs.

Among its notable ventures is Emalex Biosciences, which is developing groundbreaking treatments for central nervous system disorders, including an advanced drug for Tourette syndrome. Harmony Biosciences specializes in creating new therapies for sleep-wake disorders, having successfully commercialized the first nonscheduled treatment for narcolepsy. Evozyne leverages generative AI to design novel protein systems aimed at treating diseases with high unmet medical needs. Castle Creek Biosciences is advancing the field of gene therapies with its lead candidate, D-Fi, for dystrophic epidermolysis bullosa. Lastly, CiRC Biosciences is working towards revolutionary regenerative medicines, with a focus on restoring vision lost due to degenerative retinal diseases. Together, these companies represent Paragon's commitment to driving impactful biological advancements in healthcare.